BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35381812)

  • 1. When to use dual staining in cervical cancer screening?
    Tjalma WAA
    J Cancer Res Ther; 2022; 18(1):318-319. PubMed ID: 35381812
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond P16/Ki67 dual-stain cytology: Exploring alternative biomarkers for diagnosing cervical cancer and its precursors.
    Rauf SA; Zehra SA; Shah HH
    BJOG; 2024 Jan; 131(1):115-116. PubMed ID: 37345409
    [No Abstract]   [Full Text] [Related]  

  • 3. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
    Wentzensen N; Fetterman B; Tokugawa D; Schiffman M; Castle PE; Wood SN; Stiemerling E; Poitras N; Lorey T; Kinney W
    Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
    Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
    Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
    Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
    Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
    J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
    Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of p16/Ki-67 dual-stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer.
    Toliman PJ; Phillips S; de Jong S; O'Neill T; Tan G; Brotherton JML; Saville M; Kaldor JM; Vallely AJ; Tabrizi SN
    Clin Microbiol Infect; 2020 Jun; 26(6):748-752. PubMed ID: 31654795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population.
    Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
    Cancer Cytopathol; 2021 May; 129(5):383-393. PubMed ID: 33142029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.
    Waldstrøm M; Christensen RK; Ørnskov D
    Cancer Cytopathol; 2013 Mar; 121(3):136-45. PubMed ID: 22987560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it practical to add the p16/Ki67 immunohistochemical dual staining into liquid-based cytology for cervical cancer screening?
    Li YT; Lee NR; Chang WH
    Taiwan J Obstet Gynecol; 2024 May; 63(3):437-438. PubMed ID: 38802218
    [No Abstract]   [Full Text] [Related]  

  • 16. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
    Magkana M; Mentzelopoulou P; Magkana E; Pampanos A; Vrachnis N; Kalafati E; Daskalakis G; Domali E; Thomakos N; Rodolakis A; Anagnou NP; Pappa KI
    Anticancer Res; 2022 May; 42(5):2599-2606. PubMed ID: 35489732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
    Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
    Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic value of p16/mcm2 dual staining in cervical intraepithelial neoplasia and its association with high-risk HPV infection].
    Wang HR; Liao GD; Jiang Y; Li YC; Qiao YL; Chen W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1241-1245. PubMed ID: 28910940
    [No Abstract]   [Full Text] [Related]  

  • 20. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
    Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.